Biotalys Ending collaboration with Novonesis, new partnership with 21st.BIO

Biotalys has entered into a strategic partnership with 21st.BIO to accelerate the production of Biotalys' protein-based biocontrol solutions. Biotalys indicated that this collaboration will leverage 21st.BIO's proprietary fermentation platform to support the production of Biotalys' AGROBODY agricultural biocontrol products at commercially competitive costs.


We regret that Biotalys and Novonesis will conclude their collaboration (in line with the transition to this new agreement). Biotalys will now have to go in discussions with manufacturing and distribution partners globally to secure its commercialisation strategy. Biotalys expects to have all key arrangements in place well ahead of the launch of EVOCA NG, subject to registration which is currently foreseen for 2028-29 in the US and 2029-30 in the EU.


Biotalys confirms its cash runway into May 2026 as previously announced. They are considering additional financing through equity from institutional investors or otherwise, to fund the route to commercialization of EVOCA NG and the continued development of its portfolio of novel AGROBODY biocontrols on its technology platform. Biotalys indicated that financing could be through equity from institutional investors, including main existing shareholders or otherwise.